Clinical trial
Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as…
NCT00452985 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00452985 |
|---|---|
| Title | Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer |
| Official title | Randomised Study With Docetaxel, Cisplatin and Cyclophosphamide vs Docetaxel and Carboplatin as First Line Chemotherapy With Advanced or Metastatic Ovarian Cancer |
| Acronym | OCSTUD |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel, Carboplatin |
| Enrollment | 30 |
| Start date | Feb 1, 2002 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Mar 28, 2007 |
| Last update posted | Aug 14, 2012 |
| Countries | Bangladesh |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: